Physician profile
Amanda E Geary
NPI 1780069591
$2,578.68
in general payments reported to CMS, 2019-2025
15 companies · $276 in 2025
The $276 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $132 · 2021: $599 · 2022: $289 · 2023: $494 · 2024: $309 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,079.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,079.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $524.50 | 2019-2022 | |
| Coopervision INC. | $406.64 | 2019-2025 | Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $248.66 | 2023-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $246.45 | 2022-2025 | Xiidra, Miebo, Infuse |
| Alcon Vision LLC | $229.78 | 2019-2025 | Total30, Dailies Total1, Precision7 |
| Sight Sciences, INC. | $192.70 | 2021-2024 | Omni Surgical System |
| Aerie Pharmaceuticals, INC. | $124.76 | 2019-2020 | |
| Kala Pharmaceuticals, INC. | $121.95 | 2021 | |
| Horizon Therapeutics Plc | $120.69 | 2023 | Tepezza |
| Abbvie INC. | $99.21 | 2024 | |
| Lensar, INC. | $78.27 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $70.11 | 2023 | Lipiflow System Activator (Disposable) |
| Glaukos Corporation | $51.28 | 2021 | |
| Sun Pharmaceutical Industries INC. | $39.12 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $24.56 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Geary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.